Overview

Viravaxx is a drug development company dedicated to hepatitis B vaccine development with a lead vaccine candidate (VVX001) currently in phase II clinical trials: • Interim data confirm that VVX001 induces a preS-specific IgG antibody response in vaccine naïve adults and in chronically infected patients. • Abstracts presenting interim data were recently accepted for publication at the American Association for the Study of Liver Diseases (AASLD) and HepDART. • Viravaxx works with a board of international renowned hepatologists including Anna Lok, Fabien Zoulim, Florian van Bömmel, Patrick Kennedy and Peter Ferenci.